Results 41 to 50 of about 3,904 (202)

Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. [PDF]

Am J Nephrol
Introduction: Serum concentrations of 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D) decline as chronic kidney disease (CKD) advances, becoming insufficient without effective vitamin D repletion and driving onset of secondary ...
Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, Sprague SM.   +6 more
europepmc   +2 more sources

Bioconversion of vitamin D3 to bioactive calcifediol and calcitriol as high-value compounds

Biotechnology for Biofuels and Bioproducts, 2022
Biological catalysis is an important approach for the production of high-value-added compounds, especially for products with complex structures. Limited by the complex steps of chemical synthesis and low yields, the bioconversion of vitamin D3 (VD3) to ...
Zheyi Wang, Yan Zeng, Hongmin Jia, Niping Yang, Mengshuang Liu, Mingyue Jiang, Yanning Zheng   +6 more
doaj   +1 more source

High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report. [PDF]

BMC Nephrol
Hemodialysis (HD) patients lose renal CYP27B1 (cytochrome P450 25-hydroxyvitamin D-1α-hydroxylase) as kidney function declines causing low serum total 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), and elevated intact parathyroid hormone (
Ashfaq A, Choe J, Tabash S, Strugnell SA, Johnson LL, Bishop CW.   +5 more
europepmc   +2 more sources

Calcifediol is a safe and effective metabolite for raising vitamin D status and improving growth and feed conversion in rainbow trout [PDF]

, 2023
The vitamin D endocrine system is required for the transcriptional regulation of a myriad of vertebrate genes including those involved in bone health, growth, nutrient metabolism and immunity.
Chenal, E., Rider, S., S. Rider, B. Riond, Constant, D., Riond, B., H. Schmidt-Posthaus, R. Schoop, Schmidt-Posthaus, Heike, Schoop, R., Verlhac-Trichet, V., Etheve, S., D. Constant, V. Verlhac-Trichet, E. Chenal, S. Etheve   +15 more
core   +1 more source

Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial [PDF]

, 2021
Producción CientíficaABSTRACT Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue.
Pérez Castrillon, José Luis
core   +4 more sources

A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency. [PDF]

Nutrients
Background/Objectives: Given the crucial health benefits of vitamin D, addressing severe deficiencies is a pressing medical concern. This study aimed to evaluate the effectiveness and safety of two new weekly doses of calcifediol (100 µg and 125 µg) for ...
Pérez-Castrillón JL, Jódar-Gimeno E, Nociar J, Lojka M, Nikolov D, Cereto-Castro F, Novković S, Tarantino U, Mehsen-Cetre N, Arranz P, Martínez Ostalé C, García-Bea A, Gilaberte I.   +12 more
europepmc   +2 more sources

Vitamin D Deficiency in Obese Children Is Associated with Some Metabolic Syndrome Components, but Not with Metabolic Syndrome Itself

Metabolites, 2023
Vitamin D deficiency in children is a common nutritional issue in many populations worldwide, associated not only with skeletal malformations but, as recent studies suggest, also with the development of obesity and metabolic syndrome.
Jagoda Hofman-Hutna, Michał Hutny, Edyta Matusik, Magdalena Olszanecka-Glinianowicz, Pawel Matusik   +4 more
doaj   +1 more source

Effect of calcifediol and cholecalciferol on muscle function in postmenopausal women: a randomized controlled trial. [PDF]

Osteoporos Int
Brief rationale: Limited evidence exists on calcifediol’s effect on lower extremity function in postmenopausal women with osteoporosis or osteopenia. Main result: Calcifediol (20 µg/day) showed no greater benefit than vitamin D3 (3200 IU/day) or placebo.
Bischoff-Ferrari HA, Dawson-Hughes B, Orav JE, Ceglia L, Egli A, Kistler-Fischbacher M, Wieczorek M, de Godoi Rezende Costa Molino C.   +7 more
europepmc   +2 more sources

Calcifediol mensal versus calcifediol quinzenal no tratamento de pacientes com osteoporose.

, 2021
GOALS: To evaluate the serum concentrations of 25-hydroxyvitamin D, 25(OH)D, in osteoporotic patients treated for one year with calcifediol. METHODS: We studied 156 patients with osteoporosis (23 men and 133 women) aged 71.9 ± 9.6 years who had been ...
Olmos , J M, González Macías, J, Arnaiz , F, Olmos-Martínez , J M, Hernandez , J L   +4 more
core   +1 more source

Calcifediol high-strength formulation for vitamin D deficiency. [PDF]

Aust Prescr
europepmc   +2 more sources